1.08 (0.77, 1.51) 0.93 (0.74, 1.16) 0.84 (0.63, 1.12) 1.29 (0.24, 6.91) 1.10 (0.80, 1.52) 0.93 (0.74, 1.17) 1.50 (0.27, 8.34) 1.12 (0.39, 3.23) 0.81 (0.60,

Slides:

Advertisements

Similar presentations

חזק בהגנה לבבית Valsartan in Heart Failure

Advertisements

Efficacy and safety of angiotensin receptor blockers: a meta-analysis of randomized trials Elgendy IY et al. Am J Hypertens. 2014; doi:10,1093/ajh/hpu209.

P Fig. 6-1, p. 193 Fig. 6-2, p. 193 Fig. 6-3, p. 195.

Figure 1.1 The observer in the truck sees the ball move in a vertical path when thrown upward. (b) The Earth observer views the path of the ball as a parabola.

ADVANCE - post trial ObservatioNal Study Key results “Hot Topics in Diabetes” 50 th EASD, Vienna 2014.

UK Renal Registry 9 th Annual Report 2006 Fig 9.1 Percentage of patients with serum phosphate

Subgroup Placebo n/N (%) Serelaxin n/N (%)Favours placeboFavours serelaxin Odds ratio Estimate (95%CI) Interaction P value Total population150/580 (25.9)156/581.

UK Renal Registry 10th Annual Report 2007 Fig 3.1 Incident rates in the countries of the UK:

UK Renal Registry 17th Annual Report Figure 1.1. RRT incidence rates in the countries of the UK 1990–2013.

UK Renal Registry 10th Annual Report 2007 Fig 8.1 Median haemoglobin for incident dialysis patients at start of dialysis treatment.

Is there evidence to justify different claims for different drug classes? Presentation to: Cardiovascular & Renal Drugs Advisory Committee Food & Drug.

Relationship of background ACEI dose to benefits of candesartan in the CHARM-Added trial.

Subgroup Placebo n/N (K-M%) Serelaxin n/N (K-M%) Favours serelaxin Favours placebo Hazard ratio Estimate (95%CI) Interaction P value Total population 65/580.

UK Renal Registry 10th Annual Report 2007 Fig 9.1 Annual change in percentage of dialysis patients with serum phosphate < 1.8mmol/L and ≥1.1 -≤1.8mmol/L.

Trial profile Mann JF et al. Lancet 2008;372:

Chapter 3 Death and Survival on Dialysis Wong Hin Seng Ong Loke Meng Source: 20 th MDTR Report 2012, NRR.

Fig A. HRs with 95% CIs for age at menarche (per 1 year increase) on overall survival by clinicopathological subgroups.

Renal Replacement Therapy for Prevention of Contrast- induced Acute Kidney Injury: A Meta-analysis of Randomized Controlled Trials Source Song K, Jiang.

Analysis of Risk Factors for Early Access Failure of AVF in Patients on Hemodialysis 경희 대학교 의과대학 내과학교실 문수연, 박병조, 이향이, 정경환, 김정희, 이상호, 이태원, 임천규, 김명재.

Angiotensin converting enzyme inhibitors / angiotensin receptor blockers and contrast induced nephropathy in patients receiving cardiac catheterization:

Reducing Adverse Outcomes after ACS in Patients with Diabetes Goals

Arch Intern Med. 2004;164(13): doi: /archinte Figure Legend:

First-year death rates by modality figure 8

JOURNAL REVIEW HEART FAILURE MANAGEMENT – BETA BLOCKERS

Prevalence (pmp) of Renal Replacement Therapy

Copyright © 2011 American Medical Association. All rights reserved.

Copyright © 2011 American Medical Association. All rights reserved.

Copyright © 2014 American Medical Association. All rights reserved.

Fig 7.1 Median URR achieved in each renal unit

UK Renal Registry 16th Annual Report

Volume 376, Issue 9734, Pages (July 2010)

The Relationship Between Ultraviolet Light Exposure and Mortality in Dialysis Patients Am J Nephrol 2014;40: DOI: / Fig. 1. Association.

Is Anti-Hepatitis C Virus Antibody Level an Appropriate Marker to Preclude the Need for Supplemental Testing? Intervirology 2015;58: DOI: /

Adjusted odds ratio 95% CI Diagnostic angiography PCI CABG

CHOICE: Relative risk of death on peritoneal dialysis vs hemodialysis

Relative mortality risk associated with quartiles of systolic blood pressure compared with systolic

Mycobacterium tuberculosis infection of end-stage renal disease patients in Taiwan: a nationwide longitudinal study S.-Y. Li, T.-J. Chen, K.-W. Chung,

CHAPTER 5 Paediatric Renal Replacement Therapy

Mortality HRs for dialysis modality (PD versus HD) in 23,718 incident dialysis patients using a marginal structural model (MSM) taking into account changes.

Table 4.1: Cumulative distribution of QoL-Index score in relation to dialysis modality, all dialysis patients

CHAPTER 3 Death and Survival on Dialysis

Volume 376, Issue 9734, Pages (July 2010)

Renin-Angiotensin System Inhibitors and Kidney and Cardiovascular Outcomes in Patients With CKD: A Bayesian Network Meta-analysis of Randomized Clinical.

Early Systolic Blood Pressure Changes in Incident Hemodialysis Patients Are Associated with Mortality in the First Year Kidney Blood Press Res 2012;35:663–670.

Relative risk of major events with atenolol vs placebo

CIBIS II: Cardiac Insufficiency Bisoprolol Study II

Volume 86, Issue 5, Pages (November 2014)

The risk of hospitalization and modality failure with home dialysis

Risk of perioperative renal dysfunction with N-acetylcysteine or placebo in patients undergoing CABG surgery End point N-acetylcysteine Placebo Relative.

وضعیت موجود مرگ و میر و علل مرگ غیر مادری در افراد سال کارشناس اداره سلامت میانسالان معصومه آرشین چی همدان 27 و 28 تیرماه 1396.

CHAPTER 3 DEATHS Stephen McDonald 2012 Annual Report—35th Edition

CHAPTER 10 Hepatitis on Dialysis

UK Renal Registry 13th Annual Report

UK Renal Registry 14th Annual Report

Renin-Angiotensin System Inhibitors and Kidney and Cardiovascular Outcomes in Patients With CKD: A Bayesian Network Meta-analysis of Randomized Clinical.

UK Renal Registry 16th Annual Report

2013 Annual Report - 36th Edition

Manish M. Tanna, MD, Edward F. Vonesh, PhD, Stephen M. Korbet, MD

C.2.10 Sample Questions.

C.2.8 Sample Questions.

C.2.8 Sample Questions.

The Use of Vaccines in Adult Patients With Renal Disease

Bradley A. Warady, Mwaffek Bashir, Lynn A. Donaldson

Volume 61, Issue 2, Pages (February 2002)

Negative trials in nephrology: what can we learn?

Sagar U. Nigwekar, MD, Praveen Kandula, MD, MPH

Figure 7. Subgroup analysis according to the study design and support of CPB during CABG. The study design and support of CPB did not affect the results.

Probiotic supplementation for the first 6 months of life fails to reduce the risk of atopic dermatitis and increases the risk of allergen sensitization.

Among three residual kidney function (RKF) indices, only residual urine volume (UV) indicated an independent prognostic value in patients with UV≥0.1 or.

Presentation transcript:

1.08 (0.77, 1.51) 0.93 (0.74, 1.16) 0.84 (0.63, 1.12) 1.29 (0.24, 6.91) 1.10 (0.80, 1.52) 0.93 (0.74, 1.17) 1.50 (0.27, 8.34) 1.12 (0.39, 3.23) 0.81 (0.60, 1.10) 1.08 (0.77, 1.52) 1 .1 .5 5 10 Study Relative ratio (95% CI) p value for heterogeneity No. of trial < 1y PD ACEI < 200 >= 60y Sample size Active agent >= 200 >= 1y Age < 60y HD ARB Follow-up year Placebo Dialysis modality RASI type Control group 2 6 4 7 3 p = 0.26 p = 0.19 p = 0.59 p = 0.73 p = 0.71 p = 0.27 Favours ACEI/ARB Favours Control Fig. S1. Subgroup analysis for the relationship between all-cause mortality and the use of ACEI/ARB.